| Price Range 12mo avg: | $940K – $6.3M |
|---|---|
| $/sf 12mo avg: | $376 |
| CAP Rate 12mo avg: | 6.87% |
| NOI average: | $193,167 |
| Lease Terms: | 15yrs NN |
| Building Size avg: | 8,000 SF |
| Lot Size avg: | 0.75+/- acres |
DaVita Kidney Care is a division of DaVita HealthCare Partners Inc., a Fortune 500® company that, through its operating divisions, provides a variety of health care services to patient populations throughout the United States and abroad. A leading provider of dialysis services in the United States, DaVita Kidney Care treats patients with chronic kidney failure and end stage renal disease. DaVita Kidney Care strives to improve patients’ quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health management services. As of September 30, 2015, DaVita Kidney Care operated or provided administrative services at 2,225 outpatient dialysis centers located in the United States serving approximately 177,000 patients. The company also operated 104 outpatient dialysis centers located in 10 countries outside the United States. DaVita Kidney Care supports numerous programs dedicated to creating positive, sustainable change in communities around the world. The company’s leadership development initiatives and social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu.
DaVita—which is Italian for “giving life”—has more than 50,000 teammates (employees) around the nation working to provide superior patient care and exemplify the company’s Core Values
| S&P Credit Rating: | BB- |
|---|---|
| Moody’s Credit Rating: | Ba3 |
| Annual Revenue 2014: | $12.8B |
| Annual Revenue 2013: | $11.8B |
| Revenue Growth: | ↑ 8.13% from 2013 |
| Net Income | $723M |
| Units (Dec. 2014) | 2,179 |
| Average Units Volume: | $331856K |
Yahoo! Finance: DVA News Latest Financial News for DVA
-
Is DaVita a Suitable Stock for Value Investors?
on June 20, 2017 at 1:50 pm
Let's focus on DaVita Inc. (DVA) stock and find out if it is a good choice for value-oriented investors right now or not. […]
-
ETFs with exposure to DaVita, Inc. : June 19, 2017
on June 19, 2017 at 7:13 pm
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DaVita, Inc. Here are 5 ETFs with the largest exposure to DVA-US. Comparing the performance and risk of DaVita, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...) […]
-
Dr. David Mahoney Named Chief Medical Officer of Lifeline Vascular Access
on June 19, 2017 at 10:01 am
DENVER, June 19, 2017 /PRNewswire/ -- Lifeline Vascular Access®, a subsidiary of DaVita Inc. (DVA) and leading management company that serves providers of vascular care for patients with a variety of chronic conditions, announced the appointment of David L. Mahoney, MD, as its chief medical officer (CMO). As Lifeline's CMO, Dr. Mahoney will also serve as a member of the physician leadership team within the Office of the Chief Medical Officer at DaVita Kidney Care. […]
-
DBJ's best of the week for June 10-16: Inside the Amazon and ViaWest deals, hospital merger talks and more
on June 16, 2017 at 5:18 pm
Here's our weekly recap of some of our best web-only exclusives and stories of the week, available only to paid DBJ subscribers. (Not yet a subscriber? Click here to join us .) This week, we begin with ... […]
-
DaVita (DVA) Rolls Out Alliance Site Network for CKD Trial
on June 16, 2017 at 11:50 am
DaVita Inc (DVA), through its subsidiary DaVita Clinical Research (DCR), recently announced the expansion of its research services to include Alliance Site Network. […]
NYSE: DVA
